RNRMarketResearch.com

Neuromodulation Market to be Worth $6.8 Billion Globally by 2017

Press Release   •   Sep 27, 2014 08:33 EDT

Global neuromodulation market to be worth $6.8 billion by 2017. RNR presents analysis and discussion about neuromodulation market, its forecasts and more is now available in the global research report “Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017”. This report can be ordered at ReportsnReports.com.

Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

Complete report available at http://www.reportsnreports.com/reports/214982-neuromodulation-market-spinal-cord-stimulation-scs-vagus-nerve-stimulation-vns-gastric-electrical-stimulation-ges-deep-brain-stimulation-dbs-sacral-nerve-stimulation-sns-transcranial-magnetic-stimulation-tms-forecasts-to-2017.html .

This report estimates the neuromodulation market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Inquire for discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=214982 . (Original Price US $4650 for single user)


Table of Contents for “Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017” research report includes:

1 Introduction

2 Executive Summary

3 Market Overview

4 Global Neuromodulation Market (Internal & External)

5 Geographic Analysis

6 Competitive Landscape

7 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*

List Of Figures

Figure 1 Neuromodulation Market Segmentation
Figure 2 Market Dynamics
Figure 3 Neuromodulation Market Share Analysis, By Revenue, 2011
Figure 4 Key Growth Strategies, 2010 – 2012

Purchase a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=214982 . (This is a premium research report priced at US$ 4650 for single user PDF license).


About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. Our research specialists & industry experts, through our market research offerings, ensure we deliver on all your business & industry research requirements - first time and every time!